The EMPRESS
Pregnancy Registry

Often when a pregnant woman takes a medication, the effects of that medication on her unborn baby’s health are not usually known. This is because pregnant women are often not included in research studies. The EMPRESS Pregnancy Registry will collect information about how pregnancies and babies may, or may not, be affected by ubrogepant, an acute treatment medication for migraine.

During the study, you and your doctor(s) will be asked to share information with the registry team from both you and your baby’s routine doctor appointments. Personal information, such as age, date of birth, and any health information collected about you or your baby, will be kept confidential.

The study begins when you join the Registry and ends one year after childbirth. Participation does not involve any additional doctor's visits or changes to your current treatment plans.

You may be able to join the registry if you:

• Are at least adult age.

• Have been diagnosed with migraine.

• Are currently pregnant.

• Have not taken any migraine medications known as gepants (other than ubrogepant) shortly before or during pregnancy.

• Agree to you/your doctor/your baby’s doctor providing information about your health, pregnancy, delivery, and your baby’s health to the registry team.

• Have access to a personal smartphone, tablet or laptop.

Join the Registry

Access the Registry on your browser by clicking Web App